Role of CXCR3-induced donor T-cell migration in acute GVHD

Experimental Hematology

Volumn 31, Issue 10, 2003, Pages 897-902

  Duffner, Ulrich ^a   Lu, Bao ^c   Hildebrandt, Gerhard C ^a   Teshima, Takanori ^a   Williams, Debra L ^a   Reddy, Pavan ^a   Ordemann, Rainer ^a   Clouthier, Shawn G ^a   Lowler, Kathy ^a   Liu, Chen ^b   Gerard, Craig ^c   Cooke, Kenneth R ^a   Ferrara, James L M ^a,d  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; CHEMOKINE RECEPTOR CXCR3; CYTOKINE; GAMMA INTERFERON; MINOR HISTOCOMPATIBILITY ANTIGEN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW TRANSPLANTATION; CELL FUNCTION; CELL MIGRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; IRRADIATION; LIVER; LIVER INJURY; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMALL INTESTINE; SPLEEN; SURVIVAL; T LYMPHOCYTE; WILD TYPE;

ANIMALIA;

EID: 0141707822     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(03)00198-X     Document Type: Article

References (32)

1. Shlomchik W.D., Couzens M.S., Tang C.B., et al. Prevention of graft vs host disease by inactivation of host antigen-presenting cells. Science. 285:1999;412-415.
2. Teshima T., Ordemann R., Reddy P., et al. Acute graft-vs-host disease does not require alloantigen expression on host epithelium. Nat Med. 8:2002;575-581.
3. Krenger W., Hill G.R., Ferrara J.L. Cytokine cascades in acute graft-vs-host disease. Transplantation. 64:1997;553-558.
4. Graubert T.A., DiPersio J.F., Russell J.H., Ley T.J. Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-vs-host disease after murine bone marrow transplantation. J Clin Invest. 100:1997;904-911.
5. Baker M.B., Altman N.H., Podack E.R., Levy R.B. The role of cell-mediated cytotoxicity in acute GVHD after MHC-matched allogeneic bone marrow transplantation in mice. J Exp Med. 183:1996;2645-2656.
6. Hill G.R., Ferrara J.L. The primacy of the gastrointestinal tract as an organ of acute graft-vs-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 95:2000;2754-2759.
7. Lin T., Brunner T., Tietz B., et al. Fas ligand-mediated killing by intestinal intraepithelial lymphocytes. Participation in intestinal graft-vs-host disease. J Clin Invest. 101:1998;570-577.
8. Murai M., Yoneyama H., Ezaki T., et al. Peyer's patch is the essential site in initiating murine acute and lethal graft-vs-host reaction. Nat Immunol. 4:2003;154-160.
9. von Andrian U.H., Mackay C.R. T-cell function and migration. Two sides of the same coin. N Engl J Med. 343:2000;1020-1034.
10. Piali L., Weber C., LaRosa G., et al. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig. Eur J Immunol. 28:1998;961-972.
11. Mohan K., Ding Z., Hanly J., Issekutz T.B. IFN-γ-inducible T cell α chemoattractant is a potent stimulator of normal human blood T lymphocyte transendothelial migration: differential regulation by IFN-γ and TNF-α J Immunol. 168:2002;6420-6428.
12. Cole K.E., Strick C.A., Paradis T.J., et al. Interferon-inducible T cell α chemoattractant (I-TAC): a novel non-ELR CXC chemokine with potent activity on activated T cells through selective high-affinity binding to CXCR3. J Exp Med. 187:1998;2009-2021.
13. Weng Y., Siciliano S.J., Waldburger K.E., et al. Binding and functional properties of recombinant and endogenous CXCR3 chemokine receptors. J Biol Chem. 273:1998;18288-18291.
14. Hancock W.W., Lu B., Gao W., et al. Requirement of the chemokine receptor CXCR3 for acute allograft rejection. J Exp Med. 192:2000;1515-1520.
15. Cooke K.R., Kobzik L., Martin T.R., et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation. I.The roles of minor H antigens and endotoxin. Blood. 8:1996;3230-3239.
16. Cooke K.R., Krenger W., Hill G., et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood. 92:1998;2571-2580.
17. Hill G.R., Cooke K.R., Teshima T., et al. Interleukin-11 promotes T cell polarization and prevents acute graft-vs-host disease after allogeneic bone marrow transplantation. J Clin Invest. 102:1998;115-123.
18. Lefrancois L., Lucke N. Isolation of mouse small intestinal intraepithelial lymphocytes, Peyer's patch and lamina propria cells. Coligan J.E., Kruisbeek A.M., Margulies D.H., Shevach E.M., Strober W. Current Protocols in Immunology. Volume 1, Section 3.19:1996;John Wiley & Sons, Inc.
19. Hill G.R., Crawford J.M., Cooke K.R., Brinson Y.S., Pan L., Ferrara J.L. Total body irradiation and acute graft vs host disease. The role of gastrointestinal damage and inflammatory cytokines. Blood. 90:1997;3204-3213.
20. Teshima T., Mach N., Hill G.R., et al. Tumor cell vaccine elicits potent antitumor immunity after allogeneic T cell-depleted bone marrow transplantation. Cancer Res. 61:2001;162-171.
21. + T cells to cause lethal graft-vs-host disease across minor histocompatibility barriers in mice. J Exp Med. 165:1987;1552-1564.
22. Krenger W., Ferrara J.L.M. Dysregulation of cytokines during graft-vs-host disease. J Hematother. 5:1996;3-14.
23. Teshima T., Hill G.R., Pan L., et al. IL-11 separates graft-vs-leukemia effects from graft-vs-host disease after bone marrow transplantation. J Clin Invest. 104:1999;317-325.
24. Frigerio S., Junt T., Lu B., et al. Beta cells are responsible for CXCR3-mediated T-cell infiltration in insulitis. Nat Med. 8:2002;1414-1420.
25. Kunkel E.J., Boisvert J., Murphy K., et al. Expression of the chemokine receptors CCR4, CCR5, and CXCR3 by human tissue-infiltrating lymphocytes. Am J Pathol. 160:2002;347-355.
26. Agostini C., Calabrese F., Rea F., et al. CXCR3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol. 158:2001;1703-1711.
27. Tanaka T., Ohtsuka Y., Yagita H., Shiratori Y., Omata M., Okumura K. Involvement of α 1 and α 4 integrins in gut mucosal injury of graft-vs-host disease. Int Immunol. 7:1995;1183-1189.
28. Miura M., Morita K., Kobayashi H., et al. Monokine induced by IFN-γ is a dominant factor directing T cells into murine cardiac allografts during acute rejection. J Immunol. 167:2001;3494-3504.
29. Sauty A., Colvin R.A., Wagner L., Rochat S., Spertini F., Luster A.D. CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell α chemoattractant (CXCL11). J Immunol. 167:2001;7084-7093.
30. Murphy P.M., Baggiolini M., Charo I.F., et al. International union of pharmacology XXII. Nomenclature for chemokine receptors . Pharmacol Rev. 52:2000;145-176.
31. Korngold R., Sprent J. Features of T cells causing H-2 restricted lethal graft-vs-host disease across minor histocompatibility barriers. J Exp Med. 165:1982;1552-1564.
32. Kim Y.M., Sachs T., Asavaroengchai W., Bronson R., Sykes M. Graft-vs-host disease can be separated from graft-vs-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest. 111:2003;659-669.